Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has published an in-depth whitepaper titled "Vaccines – Global Clinical Trial Landscape (2024)." This report provides a comprehensive analysis of the evolving vaccine development landscape, offering strategic insights for biotech and pharma stakeholders.

The whitepaper examines trends in prophylactic and therapeutic vaccine trials, highlighting advancements and emerging challenges. Key topics covered include the expansion of mRNA platforms, innovative delivery methods, and efforts toward equitable vaccine access by organizations such as WHO and Gavi.

Highlights:

  • Emerging Trends: A shift towards adaptive trial designs, personalized vaccine trials, and novel delivery methods addressing infectious diseases and cancer.
  • Regional Analysis: Clinical trial activity by region, emphasizing Asia-Pacific’s increasing role in vaccine development, especially in therapeutic vaccines.
  • Investment Landscape: A summary of venture funding and M&A activity, with a focus on infectious and oncology vaccines.
  • Regulatory Developments: Insights into streamlined regulatory processes established after COVID-19, aiming to expedite vaccine approvals and enhance pandemic preparedness.

The whitepaper is available for download, providing actionable data and strategic guidance on navigating regulatory complexities, patient recruitment, and leveraging new vaccine technologies.

For more details or to access the report, click here.

Media contact

Toyna Chin

About Novotech Novotech-CRO.com 

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. 

With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. 

Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. 

Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results 

For more information or to speak to an expert team member visit www.Novotech-CRO.com